




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、CCO Independent Conference Coverage*of the 2016 ASCO Annual Meeting, June 3 -7, 2016Phase III J-ALEX: Alectinib vs Crizotinib in ALK InhibitorNaive, ALK-Positive NSCLC *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals thro
2、ugh conference coverage and other educational programs.This activity is supported by educational grants from Amgen, Ariad,Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.Alectinib in ALK InhibitorNaive ALK+ NSCLC (J-ALEX): BackgroundApproxim
3、ately 4% to 5% of white and Asian pts with advanced NSCLC have ALK gene rearrangements1Crizotinib, the first ALK inhibitor to be approved, considered standard frontline treatment of pts with ALK-positive NSCLC Crizotinib has demonstrated PFS of 10.9 mos in ALK inhibitornaive pts,2 but pts eventually
4、 relapse, mainly because of secondary ALK mutations/amplification or CNS metastasesALK inhibitor, alectinib, demonstrated activity in intracranial tumors and against ALK resistance mutations in preclinical investigation3-5AF-001 JP phase I/II study: efficacy in ALK inhibitornaive ALK+ NSCLC6, 7J-ALE
5、X: randomized phase III study of alectinib vs crizotinib in ALK inhibitornaive pts with ALK-positive NSCLC81. Chia PL, et al. Clin Epidemiol. 2014;6:423-432. 2. Solomon BJ, et al. N Engl J Med. 2014;371:2167-2177. 3. Sakamoto H, et al. Cancer Cell. 2011;19:679-690. 4. Kodama T, et al. Mol Cancer The
6、r. 2014;13:2910-2918. 5. Kodama T, et al. Cancer Chemother Pharmacol. 2014;74:1023-1028. 6. Kozuki T, et al. JSMO 2015. Abstract ISS1-2-1. 7. Takeuchi K, et al. Ann Oncol. 2016; 27:185-192. 8. Nokihara H, et al. ASCO 2016. Abstract 9008.Slide credit: Primary endpoint: PFS by independent review facil
7、ity Secondary endpoint: OS, ORR, PK, QoL, CNS PFS, safetyJ-ALEX: Study DesignAlectinib 300 mg twice daily PO28-day cycle(n = 103)Crizotinib 250 mg twice daily PO28-day cycle(n = 104)Stage IIIB/IV or recurrent ALK+ NSCLC (by IHC/FISH or RT-PCR)ECOG PS 2 1 measurable lesion (investigator assessed) 1 p
8、revious chemotherapyTreated/asymptomatic brain metastasis permitted(N = 207)Slide credit: Stratified by clinical stage (IIIB/IV vs recurrent), previous chemotherapy, ECOG PS ( 1 vs 2)1:1Nokihara H, et al. ASCO 2016. Abstract 9008.3 preplannedinterim analyses for efficacy: 33%, 50%, 75% of final even
9、ts(current report: second interim analysis)J-ALEX: Pt CharacteristicsSlide credit: CharacteristicAlectinib (n = 103)Crizotinib (n = 104)Median age, yrs (range)61.0 (27-85)59.5 (25-84)Male, n (%)41 (39.8)41 (39.4)ECOG PS, n (%)01254 (52.4)47 (45.6)2 (1.9)48 (46.2)54 (51.9)2 (1.9)Stage, n (%)IIIBIVPos
10、toperative recurrence3 (2.9)76 (73.8)24 (23.3)3 (2.9)75 (72.1)26 (25.0)Histology, n (%)%AdenocarcinomaSquamous cell carcinomaOther100 (97.1)2 (1.9)1 (1.0)103 (99.0)0 (0)1 (1.0)Brain metastasis confirmed by IRF, n (%)14 (13.6)29 (27.9)Past or current smoker, n (%)47 (45.6)43 (41.3)ALK testing method
11、IHC and FISH, n (%)96 (93.2)94 (90.4)Nokihara H, et al. ASCO 2016. Abstract 9008.J-ALEX: Efficacy Alectinib showed consistent favorable treatment effect vs crizotinib for multiple prognostic factors Brain metastases: HR: 0.08 (95% CI: 0.01-0.61)Slide credit: Nokihara H, et al. ASCO 2016. Abstract 90
12、08.OutcomeAlectinib (n = 103)Crizotinib (n = 104)HR (99.6826% CI); P ValuePFS by IRF (ITT population)Events, n (%)Median PFS, mos (95% CI)25 (24.3)NR (20.3-NR)58 (55.8)10.2 (8.2-12.0)0.34 (0.17-0.71); .0001ORR by Investigator (ITT population)ORR, % (95% CI)CR or PR, n85.4 (78.6-92.3)8870.2 (61.4-79.
13、0)73-ORRa by IRFORR, % (95% CI)CR or PR, n(n = 83)91.6 (85.6-97.5)76(n = 90)78.9 (70.5-87.3)71-a In pts with measurable disease at baseline by IRF.J-ALEX: Safety8.7% alectinib discontinuations due to AE vs 20.2% for crizotinib29.1% alectinib dose interruptions due to AE vs 74.0% for crizotinibSlide
14、credit: Nokihara H, et al. ASCO 2016. Abstract 9008.AEs ( 20%, Either Arm)Alectinib (n = 103)Crizotinib (n = 104)All GradeGrade 3/4All GradeGrade 3/4Constipation36 (35)1 (1.0)46 (44.2)1 (1.0)Nausea11 (10.7)0 (0)77 (74.0)2 (1.9)Diarrhea9 (8.7)0 (0)76 (73.1)2 (1.9)Vomiting6 (5.8)0 (0)60 (57.7)2 (1.9)A
15、ST increase11 (10.7)1 (1.0)32 (30.8)5 (4.8)ALT increase9 (8.7)1 (1.0)33 (31.7)13 (12.5)Visual disturbance1 (1.0)0 (0)57 (54.8)0 (0)Nasopharyngitis21 (20.4)0 (0)24 (23.1)0 (0)Dysgeusia19 (18.4)0 (0)54 (51.9)0 (0)Pyrexia10 (9.7)1 (1.0)21 (20.2)0 (0)Decreased appetite1 (1.0)1 (1.0)21 (20.2)1 (1.0)J-ALE
16、X: Conclusions Second preplanned interim analysis of J-ALEX shows alectinib superior to crizotinib in ALK inhibitor-naive ALK-positive NSCLC Alectinib well tolerated with fewer AE-related discontinuations or dose interruptions vs crizotinib Investigators concluded that alectinib potentially a new option for first-line therapy for ALK-positive NSCLC Global phase III ALEX trial comparing alectinib vs crizotinib in treatment-naive pts with advanced ALK-positive NSCLC ongoing (NCT02075840)Slide credit: Nokihara H, et al. ASCO
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 绿色物流与区域经济协同发展的实证分析
- 义乌工商职业技术学院《信息分析》2023-2024学年第一学期期末试卷
- 常州工程职业技术学院《阅读(二)》2023-2024学年第一学期期末试卷
- 山东圣翰财贸职业学院《科技写作专题》2023-2024学年第一学期期末试卷
- 甘孜职业学院《风景写生与创作》2023-2024学年第一学期期末试卷
- 农村区域农业产业链整合协议
- 品牌推广及广告宣传协议内容
- 家政服务与装修行业合同协议
- 苗圃技术聘用合同
- 2025年环保技术研发与应用ppp三方合同
- 普外专业 三甲医院临床试验机构GCP 2024普外 管理制度 操作规程 设计规范 应急预案
- 抗旱设备采购合同范例
- 5.3《人皆有不忍人之心》课件 统编版高中语文选择性必修上册
- 广东省河源市(2024年-2025年小学四年级语文)统编版期末考试(下学期)试卷及答案
- 2024年新人教版化学九年级上册全册课件(新版教材)
- 《跨文化传播教程》全套教学课件
- 粉刷外墙合同范本
- 三级公立医院绩效考核微创手术目录(2022版)
- JGJ-T+141-2017通风管道技术规程
- QBT 2155-2004 旅行箱包行业标准
- 医院检验科实验室生物安全程序文件SOP
评论
0/150
提交评论